SELLAS (SLS) is a publicly traded Healthcare sector company. As of July 6, 2026, SLS trades at $14.98 with a market cap of $2.95B and a P/E ratio of -59.92. SLS moved +12.43% today. Year to date, SLS is +352.57%; over the trailing twelve months it is +606.60%. Its 52-week range spans $0.77 to $15.88. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces SLS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
MassMutual Stakes Claim in SLS Ahead of Key AML Readout, Shares Extend 3-Week Rally: SLS shares have risen for a third consecutive week after MassMutual disclosed a small equity stake in the company. Investors are positioning ahead of an acute myeloid leukemia (AML) clinical readout expected later this month that could drive further volatility.
| Metric | Value |
|---|---|
| Price | $14.98 |
| Market Cap | $2.95B |
| P/E Ratio | -59.92 |
| EPS | $-0.25 |
| Dividend Yield | 0.24% |
| 52-Week High | $15.88 |
| 52-Week Low | $0.77 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-26.86M |
| Gross Margin | 0.00% |
2 analysts cover SLS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.